Delcath reports Q2 2026 financial highlights
Revenue reached $29.1 million with 30% volume growth. The company increased full-year guidance to $104-108 million and initiated a Phase 2 trial.
See the latest news and media coverage for Delcath. We track all announcements, press releases, and industry mentions in real time, all in one place.
Interventional oncology company focused on liver cancer treatments
delcath.comLast updated
In short: Delcath reported strong Q2 2026 revenue growth and raised its full-year guidance to $104-$108 million amid HEPZATO procedure expansion.
Revenue reached $29.1 million with 30% volume growth. The company increased full-year guidance to $104-108 million and initiated a Phase 2 trial.
Total revenue reached $29.1 million, up from $24.2 million year-over-year. The company increased its 2026 revenue guidance to $104-$108 million and reported cash and investments of $95.9 million.
Revenue reaches $25M, up from $19.8M. Issues $100M 2026 guidance. Highlights HEPZATO growth and CHOPIN trial publication.
CHEMOSAT Hepatic Delivery System for Melphalan is recommended as a liver-directed therapy for uveal melanoma with liver metastases. It supports improved survival from Phase 3 trials.
On August 6, Delcath Systems (NASDAQ:DCTH) reported second-quarter results that showed the company selling more of its liver cancer treatment than ever, even as the...
Shares of Delcath Systems , an interventional oncology company, advanced just over 10% on Monday, pushing the stock above its prior 52-week high.
Delcath Systems (DCTH) Q2 2026 earnings call: raised revenue guidance to $104M-$108M, expanding...
Delcath Systems (DCTH) delivered earnings and revenue surprises of +143.75% and +15.88%,...
Track Delcath and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.